Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 2475067, 8 pages
http://dx.doi.org/10.1155/2016/2475067
Review Article

Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens

Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand

Received 7 January 2016; Revised 23 February 2016; Accepted 17 April 2016

Academic Editor: Paul M. Tulkens

Copyright © 2016 Sirijan Santajit and Nitaya Indrawattana. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. S. Magill, J. R. Edwards, W. Bamberg et al., “Multistate point-prevalence survey of health care-associated infections,” The New England Journal of Medicine, vol. 370, no. 13, pp. 1198–1208, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. R. M. Klevens, J. R. Edwards, C. L. Richards Jr. et al., “Estimating health care-associated infections and deaths in U.S. Hospitals, 2002,” Public Health Reports, vol. 122, no. 2, pp. 160–166, 2007. View at Google Scholar · View at Scopus
  3. L. B. Rice, “Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE,” Journal of Infectious Diseases, vol. 197, no. 8, pp. 1079–1081, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Bush and G. A. Jacoby, “Updated functional classification of β-lactamases,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 3, pp. 969–976, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. L. B. Rice, “Progress and challenges in implementing the research on ESKAPE pathogens,” Infection Control and Hospital Epidemiology, vol. 31, supplement 1, pp. S7–S10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Giedraitienė, A. Vitkauskienė, R. Naginienė, and A. Pavilonis, “Antibiotic resistance mechanisms of clinically important bacteria,” Medicina, vol. 47, no. 3, pp. 137–146, 2011. View at Google Scholar · View at Scopus
  7. G. D. Wright, “Bacterial resistance to antibiotics: enzymatic degradation and modification,” Advanced Drug Delivery Reviews, vol. 57, no. 10, pp. 1451–1470, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. X.-Z. Li and H. Nikaido, “Efflux-mediated drug resistance in bacteria,” Drugs, vol. 64, no. 2, pp. 159–204, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. D. N. Wilson, “Ribosome-targeting antibiotics and mechanisms of bacterial resistance,” Nature Reviews Microbiology, vol. 12, no. 1, pp. 35–48, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. G. A. Jacoby and L. S. Munoz-Price, “The new beta-lactamases,” The New England journal of medicine, vol. 352, no. 4, pp. 380–391, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Džidić, J. Šušković, and B. Kos, “Antibiotic resistance mechanisms in bacteria: biochemical and genetic aspects,” Food Technology and Biotechnology, vol. 46, no. 1, pp. 11–21, 2008. View at Google Scholar · View at Scopus
  12. W.-H. Zhao and Z.-Q. Hu, “Epidemiology and genetics of CTX-M extended-spectrum β-lactamases in Gram-negative bacteria,” Critical Reviews in Microbiology, vol. 39, no. 1, pp. 79–101, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Bonnet, “Growing group of extended-spectrum β-lactamases: The CTX-M Enzymes,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 1, pp. 1–14, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Babic, A. M. Hujer, and R. A. Bonomo, “What's new in antibiotic resistance? Focus on beta-lactamases,” Drug Resistance Updates, vol. 9, no. 3, pp. 142–156, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. K. K. Kumarasamy, M. A. Toleman, T. R. Walsh et al., “Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study,” The Lancet Infectious Diseases, vol. 10, no. 9, pp. 597–602, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Yong, M. A. Toleman, C. G. Giske et al., “Characterization of a new metallo-β-lactamase gene, bla NDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 12, pp. 5046–5054, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. G. A. Jacoby, “AmpC β-lactamases,” Clinical Microbiology Reviews, vol. 22, no. 1, pp. 161–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. L. M. C. Hall, D. M. Livermore, D. Gur, M. Akova, and H. E. Akalin, “OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa,” Antimicrobial Agents and Chemotherapy, vol. 37, no. 8, pp. 1637–1644, 1993. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Danel, L. M. C. Hall, D. Gur, and D. M. Livermore, “OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa,” Antimicrobial Agents and Chemotherapy, vol. 39, no. 8, pp. 1881–1884, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. L. N. Philippon, T. Naas, A.-T. Bouthors, V. Barakett, and P. Nordmann, “OXA-18, a class D clavulanic acid-inhibited extended-spectrum β-lactamase from Pseudomonas aeruginosa,” Antimicrobial Agents and Chemotherapy, vol. 41, no. 10, pp. 2188–2195, 1997. View at Google Scholar · View at Scopus
  21. J. M. Thomson and R. A. Bonomo, “The threat of antibiotic resistance in Gram-negative pathogenic bacteria: β-lactams in peril!,” Current Opinion in Microbiology, vol. 8, no. 5, pp. 518–524, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. J. Pucci and T. J. Dougherty, “Direct quantitation of the numbers of individual penicillin-binding proteins per cell in Staphylococcus aureus,” Journal of Bacteriology, vol. 184, no. 2, pp. 588–591, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. S. S. Tang, A. Apisarnthanarak, and L. Y. Hsu, “Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria,” Advanced Drug Delivery Reviews, vol. 78, pp. 3–13, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Fukuoka, S. Ohya, T. Narita et al., “Activity of the carbapenem panipenem and role of the OprD (D2) protein in its diffusion through the Pseudomonas aeruginosa outer membrane,” Antimicrobial Agents and Chemotherapy, vol. 37, no. 2, pp. 322–327, 1993. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Sun, Z. Deng, and A. Yan, “Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations,” Biochemical and Biophysical Research Communications, vol. 453, no. 2, pp. 254–267, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Nikaido and J.-M. Pagès, “Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria,” FEMS Microbiology Reviews, vol. 36, no. 2, pp. 340–363, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. H. P. Schweizer, “Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions,” Genetics and Molecular Research, vol. 2, no. 1, pp. 48–62, 2003. View at Google Scholar · View at Scopus
  28. H. Vaez, J. Faghri, B. N. Isfahani et al., “Efflux pump regulatory genes mutations in multidrug resistance Pseudomonas aeruginosa isolated from wound infections in Isfahan hospitals,” Advanced Biomedical Research, vol. 3, article 117, 2014. View at Publisher · View at Google Scholar
  29. G. Sharma, S. Rao, A. Bansal, S. Dang, S. Gupta, and R. Gabrani, “Pseudomonas aeruginosa biofilm: potential therapeutic targets,” Biologicals, vol. 42, no. 1, pp. 1–7, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Laverty, S. P. Gorman, and B. F. Gilmore, “Biomolecular mechanisms of Pseudomonas aeruginosa and Escherichia coli biofilm formation,” Pathogens, vol. 3, no. 3, pp. 596–632, 2014. View at Publisher · View at Google Scholar
  31. J. L. del Pozo and R. Patel, “The challenge of treating biofilm-associated bacterial infections,” Clinical Pharmacology and Therapeutics, vol. 82, no. 2, pp. 204–209, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Høiby, T. Bjarnsholt, M. Givskov, S. Molin, and O. Ciofu, “Antibiotic resistance of bacterial biofilms,” International Journal of Antimicrobial Agents, vol. 35, no. 4, pp. 322–332, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. H.-A. Elsner, I. Sobottka, D. Mack, M. Claussen, R. Laufs, and R. Wirth, “Virulence factors of Enterococcus faecalis and Enterococcus faecium blood culture isolates,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 19, no. 1, pp. 39–42, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Top, R. Willems, S. van der Velden, M. Asbroek, and M. Bonten, “Emergence of clonal complex 17 Enterococcus faecium in the Netherlands,” Journal of Clinical Microbiology, vol. 46, no. 1, pp. 214–219, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. A. H. C. Uttley, N. Woodford, A. P. Johnson et al., “Vancomycin-resistant enterococci,” The Lancet, vol. 342, no. 8871, pp. 615–617, 1993. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Hope, D. M. Livermore, G. Brick, M. Lillie, and R. Reynolds, “BSAC working parties on resistance surveillance non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001–06,” Journal of Antimicrobial Chemotherapy, vol. 62, supplement 2, pp. i65–i74, 2001. View at Publisher · View at Google Scholar
  37. A. Smith, “Bacterial resistance to antibiotics,” in Hugo and Russell's Pharmaceutical Microbiology, pp. 220–232, John Wiley & Sons, 2009. View at Google Scholar
  38. C. A. Arias and B. E. Murray, “The rise of the Enterococcus: beyond vancomycin resistance,” Nature Reviews Microbiology, vol. 10, no. 4, pp. 266–278, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. N. C. Bodonakik, S. D. King, and V. R. Narla, “Antimicrobial resistance in clinical isolates of Staphylococcus aureus at the University Hospital of the West Indies,” The West Indian Medical Journal, vol. 33, no. 1, pp. 8–13, 1984. View at Google Scholar · View at Scopus
  40. P. C. Appelbaum, “Microbiology of antibiotic resistance in Staphylococcus aureus,” Clinical Infectious Diseases, vol. 45, no. 3, pp. S165–S170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. P. D. Brown and C. Ngeno, “Antimicrobial resistance in clinical isolates of Staphylococcus aureus from hospital and community sources in southern Jamaica,” International Journal of Infectious Diseases, vol. 11, no. 3, pp. 220–225, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Wu, Q. Wang, Y. Yang et al., “Epidemiology and molecular characteristics of community-associated methicillin-resistant and methicillin-susceptible Staphylococcus aureus from skin/soft tissue infections in a children's hospital in Beijing, China,” Diagnostic Microbiology and Infectious Disease, vol. 67, no. 1, pp. 1–8, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Indrawattana, O. Sungkhachat, N. Sookrung et al., “Staphylococcus aureus clinical isolates: antibiotic susceptibility, molecular characteristics, and ability to form biofilm,” BioMed Research International, vol. 2013, Article ID 314654, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. H. F. Chambers and F. R. DeLeo, “Waves of resistance: Staphylococcus aureus in the antibiotic era,” Nature Reviews Microbiology, vol. 7, no. 9, pp. 629–641, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. P. C. Appelbaum, “Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA),” International Journal of Antimicrobial Agents, vol. 30, no. 5, pp. 398–408, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Bush, G. A. Jacoby, and A. A. Medeiros, “A functional classification scheme for β-lactamases and its correlation with molecular structure,” Antimicrobial Agents and Chemotherapy, vol. 39, no. 6, pp. 1211–1233, 1995. View at Publisher · View at Google Scholar · View at Scopus
  47. A. M. Queenan and K. Bush, “Carbapenemases: the versatile β-lactamases,” Clinical Microbiology Reviews, vol. 20, no. 3, pp. 440–458, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. E. T. S. Houang, R. T. Sormunen, L. Lai, C. Y. Chan, and A. S.-Y. Leong, “Effect of desiccation on the ultrastructural appearances of Acinetobacter baumannii and Acinetobacter lwoffii,” Journal of Clinical Pathology, vol. 51, no. 10, pp. 786–788, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Biendo, G. Laurans, J. F. Lefebvre, F. Daoudi, and F. Eb, “Epidemiological study of an Acinetobacter baumannii outbreak by using a combination of antibiotyping and ribotyping,” Journal of Clinical Microbiology, vol. 37, no. 7, pp. 2170–2175, 1999. View at Google Scholar · View at Scopus
  50. J. Vila, S. Martí, and J. Sánchez-Céspedes, “Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 6, pp. 1210–1215, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. H. W. Boucher, G. H. Talbot, J. S. Bradley et al., “Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America,” Clinical Infectious Diseases, vol. 48, no. 1, pp. 1–12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. D. M. Livermore, “Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?” Clinical Infectious Diseases, vol. 34, no. 5, pp. 634–640, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Castanheira, L. M. Deshpande, D. Mathai, J. M. Bell, R. N. Jones, and R. E. Mendes, “Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006-2007,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 3, pp. 1274–1278, 2011. View at Publisher · View at Google Scholar · View at Scopus